A startup developing mass-producible platelet preparations using technology to generate platelets from human iPS cells. It aims to provide stable supplies to medical settings in developed and developing countries facing blood donation shortages, thereby supporting transfusion medicine.
背景 京都大学医学部附属病院血液内科（高折晃史教授）とCiRA（江藤浩之教授）のグループは、これまでに患者自身のiPS細胞由来血小板(注２)を使った臨床研究を実施してきました。この臨床研究は自家移植であり、...
背景 京都大学医学部附属病院血液内科（高折晃史教授）とCiRA（江藤浩之教授）のグループは、これまでにiPS細胞由来血小板（注２）を使った臨床研究を実施し、iPS細胞由来の血小板製剤の安全性について検証を行...
For the 1.2 million patients with chronic heart failure in Japan, a wristwatch-type wearable device will be used to detect heart murmurs and changes in activity levels specific to heart failure and recommend that patients seek medical attention. After the consultation, doctors will adjust oral medication, ultimately reducing re-hospitalization due to worsening heart failure.
CarbGeM is driving innovation in the life sciences through cutting-edge technologies, including regulatory-approved Software as a Medical Device (SaMD). The company empowers diagnostic support, research efficiency, and the standardization and automation of quality control. While addressing social challenges such as a shortage of skilled professionals and regional healthcare disparities, CarbGeM supports medical and industrial sectors by providing accurate and rapid results. Leveraging AI and digital platforms, the company fosters collaboration among healthcare professionals and researchers worldwide. CarbGeM is actively engaged in co-creating the future of medicine and science through open innovation with leading institutions across industry, academia, and government. The company has received numerous honors, including the Tokyo Social Innovation Tech Award 2024.
TSK is a technology startup that leverages iron-based catalytic chemistry to develop advanced functional materials. By replacing rare metals with earth-abundant iron and adopting environmentally conscious processes, we create sustainable solutions such as OLED materials and the bio-based agricultural biostimulant “Iron-Fulvo-san.” Utilizing domestic biomass as a raw material, we aim to contribute to resource circulation and decarbonization while driving innovation in next-generation chemical manufacturing.
EX-Fusion is Japan’s only private company dedicated to the commercialization of laser fusion reactors. This breakthrough technology has the potential to replace conventional energy sources and play a vital role in achieving carbon neutrality by 2050.